Abstracts tagged "Oncology"

Abstract Number: 1492 • ACR Convergence 2025
Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
Katherine Moseley¹, Dulaney Wilson², Emily Vara¹ and Diane Kamen³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder that is nine times more prevalent in women. Patients with SLE are at an…
Abstract Number: 0145 • ACR Convergence 2025
Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina
Astia Allenzara¹, Ben Albright², Xi Zhou², Amanda Nelson³, Laura Green⁴, Katherine Reeder-Hayes⁴, Jennifer Lund⁴, Caroline Thompson⁴ and Chris Baggett⁴, ¹UNC, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina, Chapel Hill
Background/Purpose: Cancer is highly prevalent and a leading cause of death for patients with Idiopathic Inflammatory Myopathies (IIM). Evaluating cancer type and stage at diagnosis…
Abstract Number: 1386 • ACR Convergence 2025
Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
Hoang Nguyen¹, Philip Moresco², Antoine Chiu², Asha Patnaik³ and Peter Gorevic⁴, ¹Stony Brook University-Renaissance School of Medicine- Department of Rheumatology, Jamaica, NY, ²Stony Brook University -Renaissance School of Medicine, Stony Brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Stony Brook University, Stony Brook, NY
Background/Purpose: -Sjogren’s syndrome (SS) is a chronic autoimmune disorder, defined by keratoconjunctivitis sicca (KCS), specific serologies, and a significant risk of extra-exocrine disease manifestations and…
Abstract Number: 1351 • ACR Convergence 2025
Are Glucocorticoids Associated with Worse Overall Survival among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
Deanna Jannat-Khah¹, Jeffrey Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York
Background/Purpose: Previous studies suggest that glucocorticoids are associated with worse survival in patients receiving immune checkpoint inhibitors (ICI). This is an important issue for Rheumatoid…
Abstract Number: 1117 • ACR Convergence 2025
Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review
Scott Yeudall¹, Mark Levis², Jonathan Webster² and Laura Cappelli³, ¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Hematopoietic stem cell transplant (HSCT) is a commonly employed treatment for hematologic malignancies including acute leukemias and lymphomas but can be complicated by graft-versus-host…
Abstract Number: 2491 • ACR Convergence 2025
High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
Marina Dueñas-Ochoa¹, Cristina Valero², Francisco Morandeira³, Juan Carlos Sáez¹, Maryia Nikitsina⁴, Montserrat Roig Kim⁵, Laia De Daniel Bisbe⁵, Esther Vicente-Rabaneda⁶, Arantza Alfranca¹, Miguel A. González-Gay⁷, Martí Aguilar Coll⁸, Rosario Garcia Vicuña⁶, Javier Narváez⁹ and Santos Castañeda¹⁰, ¹Hospital La Princesa, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ⁵Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁸Hospital Bellvitge, Barcelona, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Anti-Nucleolar Organizer Region 90 (anti-NOR90) antibodies target nucleolar proteins involved in ribosomal RNA transcription and processing, key steps in protein synthesis. These antibodies have…
Abstract Number: 1111 • ACR Convergence 2025
Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study
Maja Ivanovic¹, Daming Shao², Andrew Wang³, Craig Smuda² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL, ³University of Chicago Pritzker School of Medicine, Chicago, IL
Background/Purpose: Immune checkpoint inhibitor (ICI) induced myositis is the ICI rheumatic toxicity with the greatest case mortality rate, especially when associated with myocarditis and/or myasthenia…
Abstract Number: 2252 • ACR Convergence 2025
Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexander Peterson², Alexandra Schmidt², Katherine Wysham³, Aliyah Pabani⁴, Carolyn Presley⁵, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁶, Ariela Orkaby⁷ and Namrata Singh¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Johns Hopkins, Washington, DC, ⁵Ohio State University Medical Center, Columbus, ⁶VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁷VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a higher prevalence of frailty, even at younger ages, compared to the general population1. Among persons with lung…
Abstract Number: 1110 • ACR Convergence 2025
Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy
Madalyn Walsh¹, Jeremy Zhang², Bashar Abuqayas¹, Sanchay Jain³, Yosef Zakharia⁴, Aleksander Lenert⁵ and Jennifer Strouse⁶, ¹University of Iowa Hospitals & Clinics, Iowa City, IA, ²Rush University, Chicago, IL, ³University of Iowa, Iowa City, IA, ⁴Mayo Clinic, Rochester, MN, ⁵Iowa Carver College of Medicine, Iowa City, IA, ⁶University of Iowa, Iowa City
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of an increasing number of malignancies. Because patients with pre-existing autoimmune disease have been excluded from…
Abstract Number: 2251 • ACR Convergence 2025
Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexandra Schmidt², Alexander Peterson², Aliyah Pabani³, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁴, Noel Weiss¹ and Namrata Singh⁵, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³Johns Hopkins, Washington, DC, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of malignancies, particularly lung cancer, relative to the general population1. However, the association between RA…
Abstract Number: 1108 • ACR Convergence 2025
Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Laura Cappelli¹, Pankti Reid², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Namrata Singh¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Ami Shah¹⁵ and Clifton Bingham¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Chicago Medical Center, Chicago, IL, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Washington, Bellevue, WA, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies commonly used to treat malignancies but can cause flares or unrelated immune-related adverse events (irAEs) in patients…
Abstract Number: 2237 • ACR Convergence 2025
Safety of DMARD therapy in veterans with rheumatoid arthritis following melanoma diagnosis: a survival analysis
Gabriella Girolami¹, Shamey Kassim², Alexander Peterson³, Aaron Baraff³, Alexandra Schmidt³, Shailender Bhatia⁴, Natalie Miller⁴, Jennifer Barton⁵, Jeffrey Curtis⁶, Christopher Li⁴ and Namrata Singh⁷, ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³VA Puget Sound Health Care System, Seattle, WA, ⁴Fred Hutch Cancer Center, Seattle, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Washington, Bellevue, WA
Background/Purpose: While disease-modifying anti-rheumatic drugs (DMARDs) are critical in managing rheumatoid arthritis (RA), their immunosuppressive effects raise concerns about cancer-related outcomes. In patients with RA…
Abstract Number: 1107 • ACR Convergence 2025
Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Laura Cappelli¹, Namrata Singh², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Pankti Reid¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Clifton Bingham¹⁵ and Ami Shah¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Washington, Bellevue, WA, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Chicago Medical Center, Chicago, IL, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins University, Baltimore, MD, ¹⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Large, multi-center efforts are needed to optimally study rheumatic immune-related adverse events (rh-irAEs) from immune checkpoint inhibitor (ICI) use. We aimed to characterize the…
Abstract Number: 2121 • ACR Convergence 2025
Prevention of Bone Mass Loss Associated With Aromatase Inhibitors in Breast Cancer. A Study in Real-World Clinical Practice.
Lucía Paz Liñeira¹, Beatriz Villapún Burgoa¹, Isabel Castrejón Fernández², José María álvaro-Gracia álvaro³, Teresa González Hernández¹, Sara López Tarruella¹ and Yolanda Jerez gilarranz¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ³Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Department of Medicine, Complutense University, Madrid, Spain., Madrid, Madrid, Spain
Background/Purpose: Treatment with aromatase inhibitors (AIs) in patients with breast cancer is associated with accelerated bone mineral density (BMD) loss, leading to an increased risk…
Abstract Number: 1105 • ACR Convergence 2025
Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors
Kevin Sheng-Kai Ma¹, You Wu², Rachael Stovall², Jean Liew³ and Namrata Singh⁴, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Boston University, Boston, MA, ⁴University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs), widely used to treat a variety of cancers, are associated with immune-related adverse events (irAEs) that are increasingly encountered in…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].